Reaction of Li(ArNC(Ph)CHC(Ph)O) ((Ar)acnac; Ar = 2,4,6-Me(3)C(6)H(2)) or Na(ArNC(Ph)CHC(Ph)O) (Ar = 3,5-(t)Bu(2)C(6)H(3)) with 0.5 equiv of UO(2)Cl(2)(THF)(3) results in the formation of UO(2)((Ar)acnac)(2) (Ar = 2,4,6-Me(3)C(6)H(2), 1; 3,5-(t)Bu(2)C(6)H(3), 2), which were isolated as orange crystalline solids in good yields. The structure of 2 has been confirmed by X-ray crystallography, while the solution redox properties of 1 and 2 have been measured by cyclic voltammetry. Complex 1 exhibits a reversible reduction feature at E(1/2) = -1.52 V (vs Fc/Fc(+)), while complex 2 exhibits a reduction feature at -1.35 V (vs Fc/Fc(+)). Complexes 1 and 2 react with Cp*(2)Co to generate [Cp*(2)Co][UO(2)((Ar)acnac)(2)] (Ar = 2,4,6-Me(3)C(6)H(2), 3; 3,5-(t)Bu(2)C(6)H(3), 4), in moderate to good yields. Both 3 and 4 have been fully characterized, while the structure of 4 has also been determined by X-ray crystallography. Reaction of 2 with 2 equiv of B(C(6)F(5))(3) in CH(2)Cl(2) leads to the isolation of UO(OB{C(6)F(5)}(3))((Ar)acnac)(2) (Ar = 3,5-(t)Bu(2)C(6)H(3)) (5). Complex 5, generated in situ, exhibits an irreversible reduction at -0.78 V (vs Fc/Fc(+), 100 mV/s scan rate) which is considerably lower than the reduction potential observed for 2, consistent with the removal of electron density from the uranyl moiety by coordination of B(C(6)F(5))(3).
No takes yet. Share an insight, caveat, or question.
Hayton et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: